NLS Pharmaceutics (NLSP) Cash Funds per Single Share

The cash per share calculation indicates the liquidity of NLS Pharmaceutics AG (NLSP), where the metric value stands at 0.72. These resources fuel R&D projects aimed at creating oral therapies for ADHD and narcolepsy. The development strategy focuses on combating cognitive impairments and sleep disorders. FDA orphan drug status protects the Mazindol market, attracting patients through specialized centers in Switzerland and the US.
Analytical breakdowns for NLS Pharmaceutics AG

Management at NLS Pharmaceutics AG (NLSP) strictly limits expenses to ensure the clinical validation of its neurological developments. This figure is calculated by dividing total liquid assets by the total number of issued shares. This metric determines the business's actual financial strength per unit of capital. A high cash balance guarantees the biotech's survival until data publication, but it may signal low investment efficiency. The trend in cash per share allows for an assessment of the capital burn rate.